BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36641655)

  • 1. Prognostic factors in inflammatory breast cancer: A single-center study.
    Kridis WB; Feki A; Khmiri S; Toumi N; Chaabene K; Daoud J; Ayedi I; Khanfir A
    Breast Dis; 2022; 41(1):461-469. PubMed ID: 36641655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.
    Diessner J; Van Ewijk R; Weiss CR; Janni W; Wischnewsky MB; Kreienberg R; Hancke K; Blettner M; Wöckel A; Schwentner L
    Arch Gynecol Obstet; 2015 Sep; 292(3):655-64. PubMed ID: 25814296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative hormone receptor (HR) expression and gene expression analysis in HR+ inflammatory breast cancer (IBC) vs non-IBC.
    Iwase T; Harano K; Masuda H; Kida K; Hess KR; Wang Y; Dirix L; Van Laere SJ; Lucci A; Krishnamurthy S; Woodward WA; Layman RM; Bertucci F; Ueno NT
    BMC Cancer; 2020 May; 20(1):430. PubMed ID: 32423453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of human epidermal growth factor-like receptor 2 and hormone receptor status in inflammatory breast cancer (IBC): analysis of 2,014 IBC patient cases from the California Cancer Registry.
    Zell JA; Tsang WY; Taylor TH; Mehta RS; Anton-Culver H
    Breast Cancer Res; 2009; 11(1):R9. PubMed ID: 19228416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
    Liu ZF; Chen C; Yao XL; Sun SR
    Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distribution of molecular breast cancer subtypes among Algerian women and correlation with clinical and tumor characteristics: a population-based study.
    Cherbal F; Gaceb H; Mehemmai C; Saiah I; Bakour R; Rouis AO; Boualga K; Benbrahim W; Mahfouf H
    Breast Dis; 2015; 35(2):95-102. PubMed ID: 25736840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory breast cancer: a single centre analysis.
    Gogia A; Raina V; Deo SV; Shukla NK; Mohanti BK; Sharma DN
    Asian Pac J Cancer Prev; 2014; 15(7):3207-10. PubMed ID: 24815472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic values of negative estrogen or progesterone receptor expression in patients with luminal B HER2-negative breast cancer.
    Park C; Park K; Kim J; Sin Y; Park I; Cho H; Yang K; Bae BN; Kim KW; Ahn S; Gwak G
    World J Surg Oncol; 2016 Sep; 14(1):244. PubMed ID: 27619909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].
    Li Q; Xu BH; Zhang P; Li Q; Yuan P; Wang JY; Luo Y; Ma F; Fan Y; Li Q
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):207-11. PubMed ID: 23880002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer.
    Arias-Pulido H; Chaher N; Gong Y; Qualls C; Vargas J; Royce M
    BMC Cancer; 2012 Jul; 12():298. PubMed ID: 22813402
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Unique clinicopathological features of metaplastic breast carcinoma compared with invasive ductal carcinoma and poor prognostic indicators.
    Song Y; Liu X; Zhang G; Song H; Ren Y; He X; Wang Y; Zhang J; Zhang Y; Sun S; Liang X; Sun Q; Pang D
    World J Surg Oncol; 2013 Jun; 11():129. PubMed ID: 23738706
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term treatment efficacy in primary inflammatory breast cancer by hormonal receptor- and HER2-defined subtypes.
    Masuda H; Brewer TM; Liu DD; Iwamoto T; Shen Y; Hsu L; Willey JS; Gonzalez-Angulo AM; Chavez-MacGregor M; Fouad TM; Woodward WA; Reuben JM; Valero V; Alvarez RH; Hortobagyi GN; Ueno NT
    Ann Oncol; 2014 Feb; 25(2):384-91. PubMed ID: 24351399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of HER-2 over-expression with clinico-pathological parameters in Tunisian breast carcinoma.
    Ayadi L; Khabir A; Amouri H; Karray S; Dammak A; Guermazi M; Boudawara T
    World J Surg Oncol; 2008 Oct; 6():112. PubMed ID: 18945339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic Value of Tumor-Infiltrating Lymphocyte Density Assessed Using a Standardized Method Based on Molecular Subtypes and Adjuvant Chemotherapy in Invasive Breast Cancer.
    Jang N; Kwon HJ; Park MH; Kang SH; Bae YK
    Ann Surg Oncol; 2018 Apr; 25(4):937-946. PubMed ID: 29330719
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors for Luminal B-like Breast Cancer.
    Ding NH; Liu CF; Hu C; Yuan JQ; Liao WH; Xiao Z
    Curr Med Sci; 2019 Jun; 39(3):396-402. PubMed ID: 31209809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
    Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
    Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordance in ER, PR, HER2, and Ki-67 Expression Between Primary and Recurrent/Metastatic Lesions in Patients with Primary Early Stage Breast Cancer and the Clinical Significance: Retrospective Analysis of 75 Cases.
    Peng L; Zhang Z; Zhao D; Zhao J; Mao F; Sun Q
    Pathol Oncol Res; 2021; 27():599894. PubMed ID: 34257555
    [No Abstract]   [Full Text] [Related]  

  • 18. [Analysis of clinicopathological characteristics and prognosis for triple negative breast cancer: a report of 108 cases].
    Guan Y; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2008 Mar; 30(3):196-9. PubMed ID: 18756935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory and Non-inflammatory Breast Cancer: A Potential Role for Detection of Multiple Viral DNAs in Disease Progression.
    El-Shinawi M; Mohamed HT; Abdel-Fattah HH; Ibrahim SA; El-Halawany MS; Nouh MA; Schneider RJ; Mohamed MM
    Ann Surg Oncol; 2016 Feb; 23(2):494-502. PubMed ID: 26508152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinct outcomes in patients with different molecular subtypes of inflammatory breast cancer.
    Zhou J; Yan Y; Guo L; Ou H; Hai J; Zhang C; Wu Z; Tang L
    Saudi Med J; 2014 Nov; 35(11):1324-30. PubMed ID: 25399208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.